Display options
Cite
Gong J, Sachdev E, Mita AC, et al. Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity. World J Methodol. 2016;6(1):25-42doi: 10.5662/wjm.v6.i1.25.
Gong, J., Sachdev, E., Mita, A. C., & Mita, M. M. (2016). Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity. World journal of methodology, 6(1), 25-42. https://doi.org/10.5662/wjm.v6.i1.25
Gong, Jun, et al. "Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity." World journal of methodology vol. 6,1 (2016): 25-42. doi: https://doi.org/10.5662/wjm.v6.i1.25
Gong J, Sachdev E, Mita AC, Mita MM. Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity. World J Methodol. 2016 Mar 26;6(1):25-42. doi: 10.5662/wjm.v6.i1.25. eCollection 2016 Mar 26. PMID: 27019795; PMCID: PMC4804250.
Copy Download .nbib Format: NLM
Share it on

World J Methodol. 2016 Mar 26;6(1):25-42. doi: 10.5662/wjm.v6.i1.25. eCollection 2016 Mar 26.

Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity.

World journal of methodology

Jun Gong, Esha Sachdev, Alain C Mita, Monica M Mita

Affiliations

  1. Jun Gong, Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010, United States.

PMID: 27019795 PMCID: PMC4804250 DOI: 10.5662/wjm.v6.i1.25

Abstract

Reovirus is a double-stranded RNA virus with demonstrated oncolysis or preferential replication in cancer cells. The oncolytic properties of reovirus appear to be dependent, in part, on activated Ras signaling. In addition, Ras-transformation promotes reovirus oncolysis by affecting several steps of the viral life cycle. Reovirus-mediated immune responses can present barriers to tumor targeting, serve protective functions against reovirus systemic toxicity, and contribute to therapeutic efficacy through antitumor immune-mediated effects via innate and adaptive responses. Preclinical studies have demonstrated the broad anticancer activity of wild-type, unmodified type 3 Dearing strain reovirus (Reolysin(®)) across a spectrum of malignancies. The development of reovirus as an anticancer agent and available clinical data reported from 22 clinical trials will be reviewed.

Keywords: Clinical trial; Epidermal growth factor receptor; Immune modulation; Oncolytic virus; Preclinical; Ras; Reovirus; Type 3 Dearing

References

  1. Br J Cancer. 2011 Sep 27;105(7):1012-22 - PubMed
  2. Cancer Gene Ther. 2006 Aug;13(8):815-8 - PubMed
  3. Blood. 2002 Dec 1;100(12):4146-53 - PubMed
  4. Mol Ther. 2016 Feb;24(1):166-74 - PubMed
  5. Cancer Res. 2003 Jan 15;63(2):348-53 - PubMed
  6. J Clin Invest. 2000 Apr;105(8):1035-8 - PubMed
  7. Cancer Res. 2002 Mar 15;62(6):1696-701 - PubMed
  8. J Immunol. 2008 May 1;180(9):6018-26 - PubMed
  9. Arch Virol. 1977;54(4):307-15 - PubMed
  10. Br J Cancer. 2014 Jan 7;110(1):83-93 - PubMed
  11. Cancer Immunol Immunother. 1986;23(2):87-92 - PubMed
  12. Cancer Gene Ther. 2009 Apr;16(4):382 - PubMed
  13. Clin Cancer Res. 2009 Jul 1;15(13):4374-81 - PubMed
  14. Clin Cancer Res. 2003 Mar;9(3):1218-23 - PubMed
  15. Cancer Biol Ther. 2004 Aug;3(8):734-8 - PubMed
  16. J Virol. 1996 Jan;70(1):612-6 - PubMed
  17. Biores Open Access. 2012 Jan;1(1):3-15 - PubMed
  18. Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):91-8 - PubMed
  19. Gene Ther. 2004 Nov;11(21):1579-89 - PubMed
  20. EMBO J. 1998 Jun 15;17(12):3351-62 - PubMed
  21. Science. 1998 Nov 13;282(5392):1332-4 - PubMed
  22. Mol Ther. 2008 Mar;16(3):627-32 - PubMed
  23. Cancer Res. 2010 Jun 15;70(12 ):4912-21 - PubMed
  24. Oncol Rep. 2011 Sep;26(3):645-9 - PubMed
  25. Expert Opin Biol Ther. 2009 Jul;9(7):817-30 - PubMed
  26. Cell Death Dis. 2013 Jul 18;4:e728 - PubMed
  27. Drug Discov Today. 2005 Jun 15;10(12):847-55 - PubMed
  28. Mol Ther. 2012 Oct;20(10 ):1998-2003 - PubMed
  29. Clin Cancer Res. 2009 Jan 15;15(2):561-9 - PubMed
  30. Mol Cancer Ther. 2010 Nov;9(11):2924-33 - PubMed
  31. Hum Gene Ther. 2009 Oct;20(10):1119-32 - PubMed
  32. Int J Oncol. 2008 Aug;33(2):421-6 - PubMed
  33. J Virol. 2005 Dec;79(23):14981-5 - PubMed
  34. Cancer Res. 2003 Jun 15;63(12):3162-72 - PubMed
  35. Clin Cancer Res. 2009 Oct 1;15(19):6158-66 - PubMed
  36. Cancer Res. 2010 Mar 15;70(6):2435-44 - PubMed
  37. Cancer. 2011 Apr 15;117(8):1764-74 - PubMed
  38. Clin Cancer Res. 2012 Apr 1;18(7):2080-9 - PubMed
  39. Oncol Rep. 2008 Jun;19(6):1395-8 - PubMed
  40. Mol Cancer. 2009 Jul 14;8:47 - PubMed
  41. Clin Cancer Res. 2008 Nov 1;14(21):7127-37 - PubMed
  42. Sci Transl Med. 2012 Jun 13;4(138):138ra77 - PubMed
  43. Cancer Gene Ther. 2007 Oct;14(10):867-72 - PubMed
  44. Mol Ther. 2007 Aug;15(8):1522-30 - PubMed
  45. Mol Ther. 2007 Aug;15(8):1512-21 - PubMed
  46. Clin Cancer Res. 2008 Jan 1;14(1):259-69 - PubMed
  47. Clin Cancer Res. 2008 Feb 1;14(3):912-23 - PubMed
  48. Br J Cancer. 2011 Jan 18;104(2):290-9 - PubMed
  49. Bone Marrow Transplant. 2005 Jun;35(11):1055-64 - PubMed
  50. Clin Cancer Res. 2010 Nov 15;16(22):5564-72 - PubMed
  51. Clin Cancer Res. 2011 Feb 1;17(3):581-8 - PubMed
  52. J Natl Cancer Inst. 2001 Jun 20;93(12):903-12 - PubMed
  53. Invest New Drugs. 2013 Jun;31(3):696-706 - PubMed
  54. Methods. 2011 Oct;55(2):109-13 - PubMed
  55. Oncol Rep. 2009 Jun;21(6):1381-4 - PubMed
  56. Mol Ther. 2009 Jun;17(6):972-9 - PubMed
  57. Mol Cancer. 2011 Feb 21;10:20 - PubMed
  58. Invest New Drugs. 2010 Oct;28(5):641-9 - PubMed
  59. Clin Cancer Res. 2010 Jun 1;16(11):3067-77 - PubMed
  60. J Virol. 2002 Aug;76(15):7430-43 - PubMed
  61. Cancer Res. 1989 Sep 1;49(17):4682-9 - PubMed
  62. BMC Cancer. 2011 Jun 06;11:221 - PubMed
  63. Hum Gene Ther. 2002 Mar 20;13(5):641-52 - PubMed
  64. Leuk Res. 2010 Jan;34(1):100-8 - PubMed
  65. Bone Marrow Transplant. 2014 Jan;49(1):80-6 - PubMed
  66. Blood. 2003 Jul 1;102(1):377-87 - PubMed
  67. Clin Cancer Res. 2008 Nov 15;14(22):7358-66 - PubMed
  68. Clin Oncol (R Coll Radiol). 2008 Sep;20(7):548-54 - PubMed
  69. Cancer Gene Ther. 2008 May;15(5):284-92 - PubMed
  70. Gene Ther. 2013 May;20(5):521-8 - PubMed
  71. Int J Biochem Cell Biol. 1997 Jul;29(7):945-9 - PubMed
  72. Oncogene. 2005 Nov 21;24(52):7720-8 - PubMed
  73. Gene Ther. 2008 Dec;15(24):1567-78 - PubMed
  74. Cancer Lett. 2015 Jan 28;356(2 Pt B):846-54 - PubMed
  75. Virus Res. 2003 May;93(1):1-12 - PubMed
  76. J Virol. 1978 Nov;28(2):444-9 - PubMed
  77. BMC Cancer. 2012 Aug 24;12:368 - PubMed
  78. Mol Ther. 2011 Apr;19(4):797-804 - PubMed
  79. Clin Cancer Res. 2012 Sep 15;18(18):4962-72 - PubMed
  80. J Urol. 2004 Nov;172(5 Pt 1):2018-22 - PubMed
  81. Clin Cancer Res. 2004 Dec 15;10(24):8561-76 - PubMed
  82. Gene Ther. 2008 Jun;15(12):911-20 - PubMed
  83. Mol Cancer Res. 2012 Dec;10(12):1514-25 - PubMed
  84. Int J Oncol. 2005 Oct;27(4):901-6 - PubMed
  85. Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11099-104 - PubMed
  86. Int J Oncol. 2009 Sep;35(3):617-24 - PubMed
  87. Clin Cancer Res. 2014 Dec 1;20(23):5946-55 - PubMed
  88. Cancer Gene Ther. 2010 May;17(5):307-14 - PubMed
  89. J Neurooncol. 2011 Sep;104(3):715-27 - PubMed
  90. J Virol. 2012 Jul;86(13):7403-13 - PubMed
  91. Virology. 1993 Nov;197(1):405-11 - PubMed
  92. Mol Ther. 2014 May;22(5):1056-62 - PubMed
  93. Cancer Biother. 1995 Winter;10(4):307-15 - PubMed
  94. Mol Ther. 2010 Dec;18(12):2085-93 - PubMed
  95. Auris Nasus Larynx. 2004 Dec;31(4):407-12 - PubMed
  96. Clin Cancer Res. 2015 Mar 15;21(6):1305-12 - PubMed
  97. Gene Ther. 2008 Sep;15(18):1257-70 - PubMed
  98. MBio. 2013 Jul 02;4(4):null - PubMed

Publication Types